Advertisement Pharmaceutical Business review - Page 17 of 5210 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 15, 2024

Immuno-oncology company Portage Biotech to evaluate strategic alternatives

Clinical-stage immuno-oncology company Portage Biotech has announced plans to expand its assessment of strategic alternatives.

Continue
The company is exploring various strategic options. Credit: Darko Stojanovic from Pixabay
April 12, 2024

NICE recommends Novartis’ CAR-T therapy for leukaemia

Tisagenlecleucel will be made available for routine use on the NHS for treating B-cell acute lymphoblastic leukaemia. Credit: Colin Behrens from Pixabay.
April 11, 2024

TORL BioTherapeutics secures $158m for oncology pipeline development

The proceeds will primarily support the clinical development of TORL-1-23. Credit: Herney Gómez from Pixabay.

Contracts

December 14, 2022

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Micrograph of psoriasis vulgaris. Credit: Jenny Giang, Marc A. J. Seelen, Martijn B. A. van Doorn, Robert Rissmann,Errol P. Prens and Jeffrey Damman/ commons.wikimedia.org.

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Kite, Refuge sign license deal for gene expression platform for blood cancers

Deals

Deals March 26, 2024

Q32 Bio concludes merger deal with Homology Medicines

Pharmaceutical Business Review

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Kindeva Drug Delivery acquires Summit Biosciences

Alfasigma to acquire Galapagos’ Jyseleca business

Popular

  1. Invenra, Astellas sign bispecific antibody discovery agreement
  2. FDA approves ViiV Healthcare’s Dovato for adolescent HIV treatment
  3. US FDA grants breakthrough status to Dizal’s sunvozertinib
  4. Teva signs licensing deal with mAbxience for oncology biosimilar candidate
  5. Alterome Therapeutics secures $132m in Series B funding

PRESS RELEASES

Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK

Suppliers

Whitepapers

Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation